166 related articles for article (PubMed ID: 12540867)
41. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
Kaiser J
Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
[No Abstract] [Full Text] [Related]
42. American Society of Gene Therapy meeting. Retroviral vectors: a double-edged sword.
Kaiser J
Science; 2005 Jun; 308(5729):1735-6. PubMed ID: 15961648
[No Abstract] [Full Text] [Related]
43. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow.
Couzin J; Kaiser J
Science; 2005 Feb; 307(5712):1028. PubMed ID: 15718439
[No Abstract] [Full Text] [Related]
44. Insertional oncogenesis in gene therapy: how much of a risk?
Sadelain M
Gene Ther; 2004 Apr; 11(7):569-73. PubMed ID: 15029226
[No Abstract] [Full Text] [Related]
45. Is it going to be SIN?: a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold.
Buchholz CJ; Cichutek K
J Gene Med; 2006 Oct; 8(10):1274-6. PubMed ID: 17001625
[TBL] [Abstract][Full Text] [Related]
46. Too high a cost for a cure?
Boyce N
US News World Rep; 2002 Oct; 133(14):34. PubMed ID: 12389521
[No Abstract] [Full Text] [Related]
47. Gene therapy. Panel urges limits on X-SCID trials.
Kaiser J
Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
[No Abstract] [Full Text] [Related]
48. [Gene therapy for primary immunodeficiency diseases].
Ariga T
Nihon Rinsho; 2005 Dec; 63 Suppl 12():641-5. PubMed ID: 16416867
[No Abstract] [Full Text] [Related]
49. Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis.
Cichutek K
Dev Biol (Basel); 2006; 123():29-34; discussion 55-73. PubMed ID: 16566434
[No Abstract] [Full Text] [Related]
50. Temporary halt on gene therapy trials.
FDA Consum; 2003; 37(2):6. PubMed ID: 12715756
[No Abstract] [Full Text] [Related]
51. US authorities uphold suspension of SCID gene therapy.
Fox JL
Nat Biotechnol; 2003 Mar; 21(3):217. PubMed ID: 12610555
[No Abstract] [Full Text] [Related]
52. Gene therapy.
Heslop HE
Cytotherapy; 2007; 9(6):519-20. PubMed ID: 17882715
[No Abstract] [Full Text] [Related]
53. French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.
European Society of Gene Therapy
J Gene Med; 2003 Jan; 5(1):82-4. PubMed ID: 12516054
[No Abstract] [Full Text] [Related]
54. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia.
Bank A; Dorazio R; Leboulch P
Ann N Y Acad Sci; 2005; 1054():308-16. PubMed ID: 16339679
[TBL] [Abstract][Full Text] [Related]
55. FDA halts 27 gene therapy trials after illness: leukemia-like cases in 2 children in France prompt the action.
Pollack A
N Y Times Web; 2003 Jan; ():A1, A17. PubMed ID: 12647754
[No Abstract] [Full Text] [Related]
56. Therapy on trial.
Hughes V
Nat Med; 2007 Sep; 13(9):1008-9. PubMed ID: 17828211
[No Abstract] [Full Text] [Related]
57. Gene therapy: therapeutic gene causing lymphoma.
Woods NB; Bottero V; Schmidt M; von Kalle C; Verma IM
Nature; 2006 Apr; 440(7088):1123. PubMed ID: 16641981
[TBL] [Abstract][Full Text] [Related]
58. Gene therapy for immune disorders: good news tempered by bad news.
Puck JM; Malech HL
J Allergy Clin Immunol; 2006 Apr; 117(4):865-9. PubMed ID: 16630946
[TBL] [Abstract][Full Text] [Related]
59. For gene therapy, now-quantified risks are deemed troubling.
Twombly R
J Natl Cancer Inst; 2003 Jul; 95(14):1032-3. PubMed ID: 12865444
[No Abstract] [Full Text] [Related]
60. Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells.
Dropulic B
Curr Hematol Rep; 2005 Jul; 4(4):300-4. PubMed ID: 16009045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
